During the past decade, Hiroshima Clinical Site1 conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hiroshima Clinical Site1" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Hiroshima Clinical Site1" are "Gastric Cancer" (2 trials). Many other conditions were trialed in "Hiroshima Clinical Site1" in a lesser frequency.

Most popular intervention types in "Hiroshima Clinical Site1" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Capecitabine" (2 trials), "Oxaliplatin" (2 trials), "Placebo" (2 trials), "Nivolumab" (1 trials) and "ONO-4538" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hiroshima Clinical Site1" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Hiroshima Clinical Site1". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Hiroshima Clinical Site1, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hiroshima Clinical Site1, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".